Final approval for Kos' Advicor

KOSP received final marketing approval for its extended release Advicor niacin/lovastatin to treat cholesterol disorders. The company received an approvable letter from the FDA for the product in July, and final approval followed an inspection of KOSP's manufacturing facilities and the expiration of the exclusivity period on Dec. 15 for lovastatin, which is marketed by Merck (MRK) under the name Mevacor. ...